Table 2.
Analysis of False Positive Rate and Demographic Covariates
| Normal | Resolved – False Positive | # Unresolved |
||||
|---|---|---|---|---|---|---|
| Analyte | Variable | Mean (1-99%tile) | # (%) | Mean (1-99%tile) | # (%) | |
| 17-OHP1 | Gestational Age | |||||
| 24-32 weeks | 68.7 (11-182.5) | 1,695 (91.1.8%) | 188.4 (54.5-230) | 158 (8.5%) | 8 (0.4%) | |
| 32-36 weeks | 28.1 (6-105) | 16,037 (95.7%) | 102.5 (46.5-207) | 680 (4.1%) | 38 (0.2%) | |
| 37-42 weeks | 14.7 (5-43) | 202,850 (99.8%) | 89.4 (39-185) | 277 (0.1%) | 38 (0.02%) | |
| Birth Weight | ||||||
| <=1,250 grams | 74.6 (12.5-187) | 900 (89.2%) | 202.7 (137.5-230) | 103 (10.2%) | 6 (0.6%) | |
| 1,250g-1749.9 | 51.4 (7-146.5) | 1,633 (96.5%) | 167.7 (90.5-230) | 57 (3.4%) | 2 (0.1%) | |
| 1,750g-2,249.9 | 32.7 (6-124) | 5,116 (98.4%) | 132.5 (59.5-230) | 81 (1.6%) | 2 (0.04%) | |
| >=2,250 grams | 15.2 (5-48.5) | 212,933 (99.6%) | 95.0 (44-195.5) | 874 (0.4%) | 74 (0.03%) | |
| Gender | ||||||
| Male | 17.2 (5-65.5) | 112,062 (99.3%) | 110.2 (50-230) | 711 (0.63%) | 54 (0.05%) | |
| Female | 14.9 (5-61.5) | 107,596 (99.6%) | 113.6 (44-230) | 402 (0.37%) | 27 (0.02%) | |
| MS/MS2 | Gestational Age | |||||
| PHE | 24-32 weeks | 73.2 (38.7-125.7) | 1,139 (89.8%) | 137.4 (57.3-415.2) | 126 (9.9%) | 4 (0.3%) |
| 32-36 weeks | 60.2 (37.1-100.6) | 15,302 (98.9%) | 115.3 (43.4-428.8) | 144 (0.9%) | 33 (0.2%) | |
| 37-42 weeks | 57.3 (37.7-88.9) | 202,015 (99.8%) | 84.1 (41.5-423.1) | 337 (0.2%) | 171 (0.1%) | |
| C0 | Gender | |||||
| Male | 20.2 (8.7-43.1) | 110,934 (99.6%) | 28.1 (9.7-78.7) | 343 (0.31%) | 122 (0.11%) | |
| Female | 18.4 (8.1-38.9) | 106,599 (99.7%) | 24.4 (4.5-83.4) | 264 (0.25%) | 86 (0.08%) | |
| C4 | Gender | |||||
| Male | 0.25 (0.09-0.71) | 110,934 (99.6%) | 0.42 (0.12-1.6) | 343 (0.31%) | 122 (0.11%) | |
| Female | 0.26 (0.09-0.71) | 106,599 (99.7%) | 0.46 (0.10-1.9) | 264 (0.25%) | 86 (0.08%) | |
| C16 | Gender | |||||
| Male | 3.1 (1.3-5.9) | 110,934 (99.6%) | 3.3 (0.63-9.1) | 343 (0.31%) | 122 (0.11%) | |
| Female | 2.9 (1.2-5.5) | 106,599 (99.7%) | 2.8 (0.64-7.3) | 264 (0.25%) | 86 (0.08%) | |
| C12 | Gender | |||||
| Male | 0.27 (0.08-0.77) | 110,934 (99.6%) | 0.31 (0.05-1.4) | 343 (0.31%) | 122 (0.11%) | |
| Female | 0.25 (0.08-0.70) | 106,599 (99.7%) | 0.27 (0.05-0.98) | 264 (0.25%) | 86 (0.08%) | |
| TSH | Season | |||||
| Winter (Dec-Feb) | 8.3 (2.2-22.1) | 52,215 (98.8%) | 28.4 (25-53.3) | 464 (0.9%) | 175 (0.3%) | |
| Spring (Mar-May) | 8.0 (2.2-21.5) | 55,389 (99.2%) | 28.1 (25-52.1) | 326 (0.6%) | 128 (0.2%) | |
| Summer (Jun-Aug) | 7.9 (2.2-21.2) | 57,310 (99.3%) | 27.9 (25-46.4) | 329 (0.6%) | 94 (0.2%) | |
| Fall (Sep-Nov) | 8.1 (2.2-21.8) | 54,830 (99.1%) | 27.9 (25-52.6) | 368 (0.7%) | 145 (0.3%) | |
1
threshold values for an abnormal test result for 17-OHP are based on birth weight thresholds and changed in 2007.
2
False positive results are grouped for all disorders tested on MS/MS including fatty acid, amino acid and organic acid disorders.